Aimmune Therapeutics Company Profile
8000 Marina Boulevard
Brisbane CA 94005
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of desensitization treatments for peanut and other food allergies. Its Characterized Oral Desensitization Immunotherapy includes AR101, a product in Phase 3 registration trial for the treatment of peanut allergy in children and adults. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.